Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Halozyme Therapeutics Inc. Common StockTrade

Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Halozyme Therapeutics Inc. Common Stock vs Vanguard S&P 500 ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.27 (market cap $12.58B), while Vanguard S&P 500 ETF trades at $715.64 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 143.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Vanguard S&P 500 ETF is more actively traded (4,722,271 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Vanguard S&P 500 ETF for 55 Days on average.

	HALO	VOO
Market Cap	$12.58B	$1.80T
Volume	2,179,278	4,722,271
Sector	Health	Broad Market / Factor
52-Week High	$115.22	$716.17
52-Week Low	$61.63	$580.93
Typical Hold Time	1 Days	55 Days
Enterprise Value	$14.49B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Halozyme Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Vanguard S&P 500 ETF

VOO trades at $715.68, up 0.18% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building despite short interest increasing 46.9% in September. Dividend yield remains modest with the next payment scheduled for September 30, 2026.

Outlook remains positive given S&P 500 exposure and historical resilience, though risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated short interest. The ETF's low-cost structure and diversification provide stability amid market volatility, making it suitable for core portfolio holdings.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HALO

No sentiment data available yet.

VOO

72% Buy28% Sell

Avg holding period · 55 Days

Top news

Latest headlines on both assets

HALO

View details →

VOO

Waiting two months after tariff crash to buy VOO cost investors $1,500 per $10,000 invested.24/7 Wall Street · 6 hours agoBullish Two S&P 500 ETFs charge just 0.03% fees, beating the well-known SPY's 0.0945% expense ratio.24/7 Wall Street · 1 day agoNeutral Vanguard S&P 500 ETF preferred over Invesco QQQ for stable, long-term wealth growth.Seeking Alpha · 3 days agoBullish View details →

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.